EGFR and non-small cell lung carcinoma: The gefitinib data reported here are also in agreement with results of a recently reported phase IV study of gefitinib in Caucasian patients with EGFR mutation-positive NSCLC (n = 106), which observed a median PFS of 9.7 months [112].